Remsima Indications and Usage

  • RemsimaTM is a tumor necrosis factor α (TNF-α) antagonist used to treatrheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, plaque psoriasis, and psoriatic arthritis.
  • Rheumatoid Arthritis
    RemsimaTM, in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with methotrexate to severe cases of rheumatoid arthritis.
  • Ankylosing Spondylitis
    RemsimaTM, in combination with methotrexate for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with methotrexate to severe cases of rheumatoid arthritis.
  • Adult Crohn's Disease
    RemsimaTM is indicated for reducing signs and symptoms as well as inducing and maintaining clinical remission in adult patients including and maintatining clinical remission in adult patients with moderate to severe cases of Crohn's disease who have had an inadequate response to conventional therapy.
  • Ulcerative Colitis
    RemsimaTM is indicated for reducing signs and symptoms, inducing and maintatining clinical remission and mucosal healing and eliminating corticosteroid use in adult patients with moderate to severe cases of ulcerative colitis who have had an inadequate response to conventional therapy.
  • Psoriatic Arthritis
    RemsimaTM is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.
  • Plaque Psoriasis
    RemsimaTM is indicated for the treatment of adult patients with chronic severe plaque psoriasis for whom other systemic therapies are medically less appropriate. Remsima should only be administered to patients who will be closely supervised and have regular follow-up visits with a physician.